Paris - Delayed Quote EUR

MedinCell S.A. (MEDCL.PA)

26.36 +0.10 (+0.38%)

At close: October 30 at 5:35:28 PM GMT+1

Is MedinCell (ENXTPA:MEDCL) Trading Above Fair Value On Sales?

Simply Wall St. 18h ago

MEDCL.PA
+0.38%
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Business Wire 18d ago

MEDCL.PA
+0.38%
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Business Wire 18d ago

MEDCL.PA
+0.38%
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Business Wire 19d ago

MEDCL.PA
+0.38%
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Business Wire 19d ago

MEDCL.PA
+0.38%
Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Business Wire 23d ago

MEDCL.PA
+0.38%
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Business Wire 23d ago

MEDCL.PA
+0.38%
TEVA
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Business Wire 23d ago

MEDCL.PA
+0.38%
TEVA
Medincell Announces the Temporary Suspension of Trading in Its Shares on Euronext Paris

Business Wire 23d ago

MEDCL.PA
+0.38%
Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. Today

Business Wire 1mo ago

MEDCL.PA
+0.38%
Medincell to Participate in Upcoming Investor Conferences

Business Wire 1mo ago

MEDCL.PA
+0.38%
Medincell to Participate in Upcoming Investor Conferences

Business Wire 1mo ago

MEDCL.PA
+0.38%

U.S. markets closed

MedinCell S.A. (MEDCL.PA)

Is MedinCell (ENXTPA:MEDCL) Trading Above Fair Value On Sales?

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell Announces the Temporary Suspension of Trading in Its Shares on Euronext Paris

Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. Today

Medincell to Participate in Upcoming Investor Conferences

Medincell to Participate in Upcoming Investor Conferences